Prostate Cancer Update 1

Select Publications

Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321(7):419-24. Abstract

D’Amico AV et al. Time to return to baseline testosterone level and the risk of death from prostate cancer in men who received radiation and 6 months of androgen suppression therapy. Proc ASCO Prostate Cancer Symposium 2007;Abstract 190.

D’Amico AV et al. The influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction. Proc ASTRO 2006;Abstract 2239.

Dearnaley DP et al. Early efficacy and late toxicity of escalated-over-standard-dose conformal radiotherapy with neo-adjuvant androgen suppression for men with localized prostate cancer: First results of MRC RT01 trial (ISRCTN47772397). Proc ASCO Prostate Cancer Symposium 2007;Abstract 295.

Eisenberger MA et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339(15):1036-42. Abstract

Jemal A et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. Abstract Available at: www.seer.cancer.gov.

Keating NL et al. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-56. Abstract

Pollack A et al. Prostate cancer radiation dose response: Results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:(5):1097-105. Abstract

Sweeney CJ. ECOG: CHAARTED — ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin Adv Hematol Oncol 2006;4(8):588-90. No abstract available

Taplin ME et al. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006;24(34):5408-13. Abstract

Tsai HK et al. Androgen deprivation therapy for prostate cancer and the risk of cardiac mortality. Proc ASCO Prostate Cancer Symposium 2007;Abstract 298.

Valicenti RK et al. RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys 2003;57(3):614-20. Abstract